Dulaglutide: first global approval.

Article Details

Citation

Copy to clipboard

Sanford M

Dulaglutide: first global approval.

Drugs. 2014 Nov;74(17):2097-103. doi: 10.1007/s40265-014-0320-7.

PubMed ID

25367716 [ View in PubMed

]

Abstract

Dulaglutide (Trulicity) is a long-acting, glucagon-like peptide-1 (GLP-1) receptor agonist that has been developed by Eli Lilly and Company for the treatment of type 2 diabetes mellitus. It consists of a dipeptidyl peptidase-IV-protected GLP-1 analogue covalently linked to a human IgG4-Fc heavy chain by a small peptide linker. The subcutaneous formulation is approved for use in type 2 diabetes in the US, has been recommended for approval in the EU in this indication, and is under regulatory review in other countries. This article summarizes the milestones in the development of subcutaneous dulaglutide leading to this first approval for type 2 diabetes.

DrugBank Data that Cites this Article

Drugs

Dulaglutide

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Dulaglutide	Glucagon-like peptide 1 receptor	Protein	Humans	Yes	Agonist	Details